Skip to main content
NCBI home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2005 Jul 15;19(4):133–138. doi: 10.1002/jcla.20067

Interleukin‐1‐β gene, but not the interleukin‐1 receptor antagonist gene, is associated with graves' disease

Rong‐Hsing Chen 1, Wen‐Chi Chen 2,3, Chwen‐Tzuei Chang 1, Chang‐Hai Tsai 4,5, Fuu‐Jen Tsai 3,4,✉
PMCID: PMC6807985  PMID: 16025481

Abstract

Interleukin‐1 (IL‐1) is considered to be involved in the pathogenesis of Graves' disease. The aim of this study was to test whether the IL‐1‐β gene promoter region and exon 5 and IL‐1 receptor antagonist (IL‐1Ra) gene intron 2 polymorphisms could be useful genetic markers for susceptibility to Graves' disease. A normal control group of 163 healthy people and another group of 95 patients with Graves' disease were examined. Polymerase chain reaction (PCR) was used to analyze the variable number of tandem repeats (VNTRs) at intron 2 of the IL‐1Ra gene for the polymorphism. PCR‐based restriction analysis was done for the IL‐1‐β gene polymorphisms of the promoter region and exon 5 using endonucleases AvaI and TaqI, respectively. We found significantly increased frequencies of the C/C homozygous genotype (χ2 test, P=0.038; odds ratio (OR)=2.558, 95% confidence interval (CI)=1.205–5.430) and the C allele (χ2 test, P=0.011; OR=1.589, 95% CI=1.094–2.309) in the IL‐1‐β gene promoter (−511 C/T polymorphism) in Graves' disease patients compared to normal controls. There were no significant differences in polymorphisms of IL‐1‐β gene exon 5 and IL‐1Ra gene intron 2 between the patient and normal control groups. A subgroup analysis also demonstrated no association between the severity of the disease and any polymorphism of IL‐1‐related genes. We suggest that the IL‐1‐β gene promoter polymorphism can be used as a genetic marker for susceptibility to Graves' disease. It is worthwhile to study the cytokine genes further because of the association between cytokines and Graves' disease. J. Clin. Lab. Anal. 19:133–138, 2005. © 2005 Wiley‐Liss, Inc.

Keywords: interleukin‐1‐β, interleukin‐1 receptor antagonist, Graves' disease, single nucleotide polymorphisms (SNPs)

REFERENCES

  • 1. Larsen PR, Alexander NM, Chopra IJ, et al. Revised nomenclature for tests of thyroid hormones and thyroid‐related proteins in serum. J Clin Endocrinol Metab 1987;64:1089–1092. [DOI] [PubMed] [Google Scholar]
  • 2. Di Paola R, Menzaghi C, De Filippis V, Corda D, Di Cerbo A. Cyclooxygenase‐dependent thyroid cell proliferation induced by immunoglobulins from patients with Graves' disease. J Clin Endocrinol Metab 1997;82:670–673. [DOI] [PubMed] [Google Scholar]
  • 3. Kelso A. Cytokines: principles and prospects. Immunol Cell Biol 1998;76:300–317. [DOI] [PubMed] [Google Scholar]
  • 4. Dinarello CA, Wolff SM. The role of interleukin‐1 in disease. N Engl J Med 1993;328:106–113. [DOI] [PubMed] [Google Scholar]
  • 5. Rosenwasser LJ. Biologic activities of IL‐1 and its role in human disease. J Allergy Clin Immunol 1998;102:344–350. [DOI] [PubMed] [Google Scholar]
  • 6. Kawabe Y, Eguchi K, Shimomura C, et al. Interleukin‐1 production and action in thyroid tissue. J Clin Endocrinol Metab 1989;68:1174–1183. [DOI] [PubMed] [Google Scholar]
  • 7. Miyazaki A, Hanahusa T, Itoh N, et al. Demonstration of interleukin‐1β on perifollicular endothelial cells in the thyroid glands of patients with Graves' disease. J Clin Endocrinol Metab 1989;69:738–744. [DOI] [PubMed] [Google Scholar]
  • 8. McDowell TL, Symons JA, Ploski R, Forre O, Duff GW. A genetic association between juvenile rheumatoid arthritis and a novel interleukin‐1α polymorphism. Arthritis Rheum 1995;38: 221–228. [DOI] [PubMed] [Google Scholar]
  • 9. Blakemore AIF, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. Interleukin‐1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994;37:1380–1385. [DOI] [PubMed] [Google Scholar]
  • 10. Mansfield JC, Holden H, Tarlow JK, et al. Novel genetic association between ulcerative colitis and the anti‐inflammatory cytokine interleukin‐1 receptor antagonist. Gastroenterology 1994;106:637–642. [DOI] [PubMed] [Google Scholar]
  • 11. Tarlow JK, Clay FE, Cork MJ, Blakemore AIF, McDonagh AJG, Messenger AG. Severity of alopecia areata is associated with a polymorphism in the interleukin‐1 receptor antagonist gene. J Invest Dermatol 1994;103:387–390. [DOI] [PubMed] [Google Scholar]
  • 12. Cantagrel A, Navaux F, Loubet‐Lescoulie P, Nourhashemi F, Enault G, Abbal M. Interleukin‐1β, interleukin‐1 receptor antagonist, interleukin‐4, and interleukin‐10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999;42:1093–1100. [DOI] [PubMed] [Google Scholar]
  • 13. Langdahl BL, Lokke E, Carstens M, Stenkjaer LL, Eriksen EF. Osteoporotic fractures are associated with an 86‐base pair repeat polymorphism in the interleukin‐1 receptor antagonist gene but not with polymorphisms in the interleukin‐1β gene. J Bone Miner Res 2000;15:402–414. [DOI] [PubMed] [Google Scholar]
  • 14. Blakemore AIF, Watson PF, Weetman AP, Duff GW. Association of Graves' disease with an allele of the interleukin‐1 receptor antagonist gene. J Clin Endocrinol Metab 1995;80:111–115. [DOI] [PubMed] [Google Scholar]
  • 15. Cuddihy RM, Bahn RS. Lack of an association between alleles of interleukin‐1α and interleukin receptor antagonist genes and Graves' disease in a North American Caucasian population. J Clin Endocrinol Metab 1996;81:4476–4478. [DOI] [PubMed] [Google Scholar]
  • 16. Muhlberg T, Kirchberger M, Spitzwig C, Herrmann F, Heberling HJ, Heufelder AE. Lack of association of Graves' disease with the A2 allele of the interleukin‐1 receptor antagonist gene in a white Europe population. Eur J Endocrinol 1998;138:686–690. [DOI] [PubMed] [Google Scholar]
  • 17. Heward JM, Allahabadia A, Daykin J, et al. Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family‐based study. J Clin Endocrinol Metab 1998;83:3394–3397. [DOI] [PubMed] [Google Scholar]
  • 18. Chen QY, Huang W, She JX, Baxter F, Volpe R, Maclaren MK. HLA‐DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves' disease in North American Caucasians, whereas DRB1*07 is protective. J Clin Endocrinol Metab 1999;84:3182–3186. [DOI] [PubMed] [Google Scholar]
  • 19. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGgroot LJ. CTLA‐4 gene polymorphism associated with Graves' disease in Caucasian population. J Clin Endocrinol Metab 1995;80:41–45. [DOI] [PubMed] [Google Scholar]
  • 20. Davies TF. Editorial: autoimmune thyroid disease genes come in many styles and colors. J Clin Endocrinol Metab 1998;83:3391–3393. [DOI] [PubMed] [Google Scholar]
  • 21. Tomer Y, Barbesino G, Greenberg DA, Concepcion E, Davis TF. Linkage analysis of candidate genes in autoimmune thyroid disease. III. Detailed analysis of chromosome 14 localizes Graves' disease‐1 (GD‐1) close to multinodular goiter‐1 (MNG‐1). J Clin Endocrinol Metab 1998;83:4321–4327. [DOI] [PubMed] [Google Scholar]
  • 22. Tomer Y, Barbesino G, Greenberg DA, Concepcion ES, Davis TF. A new Graves' disease‐susceptibility locus maps to chromosome 20q11.2. Am J Hum Genet 1998;63:1749–1756. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Barbesino G, Tomer Y, Concepcion ES, Davis TF, Greenberg DA. Linkage analysis of candidate genes in autoimmune thyroid disease. II. Selected gender‐related genes and the X‐chromosome. J Clin Endocrinol Metab 1998;83:3290–3295. [DOI] [PubMed] [Google Scholar]
  • 24. Bahn RS, Dutton CM, Heufelder AE, Sarker G. A genomic point mutation in the extracellular domain of the thyrotropin receptor in patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1994;78:256–260. [DOI] [PubMed] [Google Scholar]
  • 25. Bluher M, Krohn K, Wallaschofski H, Braverman LE, Paschke R. Fas and Fas ligand gene expression in autoimmune thyroiditis in BB/W rats. Eur J Endocrinol 1999;141:506–511. [DOI] [PubMed] [Google Scholar]
  • 26. Stuck BJ, Pani MA, Besrour F, et al. Fas ligand gene polymorphisms are not associated with Hashimoto's thyroiditis and Graves' disease. Hum Immunol 2003;64:285–289. [DOI] [PubMed] [Google Scholar]
  • 27. Kriss JP, Pleshakov V, Chien JR. Isolation and identification of the long‐acting thyroid stimulator and its relation to hyperthyroidism and circumscribed pretibial myxedema. J Clin Endocrinol 1964;24:1005–1028. [DOI] [PubMed] [Google Scholar]
  • 28. Romagnani S. Th1 and Th2 in human diseases Short analytic review. Clin Immunol Immunopathol 1996;80:225–235. [DOI] [PubMed] [Google Scholar]
  • 29. Kocjan T, Wraber B, Repnik U, Hojker S. Changes in Th1/Th2 cytokine balance in Graves' disease. Eur J Physiol 2000; 400(suppl 400):94–95. [PubMed] [Google Scholar]
  • 30. Manetti R, Barak V, Piccinni MP, et al. Interleukin‐1 favours the in vitro development of the type 2 helper (Th2) human T‐cell clones. Res Immunol 1994;145:93–100. [DOI] [PubMed] [Google Scholar]
  • 31. Chensue SW, Bienkowski M, Eessalu TE, et al. Endogenous IL‐1 receptor antagonist protein (IRAP) regulates Schistosome egg granuloma formation and the regional lymphoid response. J Immunol 1993;151:3654–3662. [PubMed] [Google Scholar]
  • 32. Bensen JT, Dawson PA, Mychaleckyj JC, Bowden DW. Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2q12‐14. J Interferon Cytokine Res 2001;21:899–904. [DOI] [PubMed] [Google Scholar]
  • 33. Rasmussen AK, Bech K, Feldt‐Rasmussen U, et al. Interleukin‐1 affects the function of cultured human thyroid cells. Allergy 1998:435–441. [DOI] [PubMed] [Google Scholar]
  • 34. Mandrup‐Poulsen T, Pociot F, Molvig J, et al. Monokine antagonism is reduced in patients with IDDM. Diabetes 1994;43:1242–1247. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES